Regional Account Manager - Hematology
About the job
- Optimum 3 years Biotechnology/Pharmaceutical sales experience preferably in the orphan market area or alternatively absolvents with a Master of Science in Biology, Chemistry or comparable and a strong selling and performance orientated mindset
- Ability to work effectively independently and in a team-oriented environment on a consistent basis
- Ability and experience in project management of scientific events
- Ability to gain consistent access & develop strong, professional relationships for scientific exchange and product promotion with healthcare providers in community and academic centers
- Influential presentation style with demonstrated ability to uncover and address customer needs and effectively manage customer concerns and questions
- The flexibility to work in different areas of indication and with different target groups when these are assigned to your scope of responsibility
- Excellent verbal and written communication skills and organizational abilities
- Microsoft Office experience essential (Outlook, Power point, Word, Excel) and
- Reporting Tools
- Knowledge and understanding of country pharmaceutical regulations
- Ability to travel within territory on a regular basis which will include overnight travel
- Valid driver’s license and clean driving record
- Establish and maintain contacts to office-based and hospital Hematologists, and other relevant specialties, pharmacists, nurses and other relevant hospital personnel to establish and maintain a valuable business relationship to customers for Alexion
- Create a positive image of Alexion Pharma Germany GmbH with relevant customer groups
- Detailed analysis of area with the objective to detect and develop relevant centers for the rare diseases in Hematology
- Provide educational and commercial services to hospital and office-based physicians and relevant pharmacies
- Selling Alexion products within legal boundaries according to Alexion’s marketing and sales strategy
- Self-dependent planning, organization, and execution of local educational sessions for relevant healthcare professionals
- Actively look for cross-functional collaboration (Marketing, MSL, DLS, MACC) and cross-functional account management
- Timely and complete reporting to senior positions and accurate maintenance of the CRM database and of account management
- Collect and report pharmacovigilance information according to internal SOPs
- Represent the territory in regular territory reviews and account plan discussions
- Represent Alexion Pharma Germany GmbH at national and international events and congresses
- Obey data protection law according Alexion's policy and follow Alexion's SOPs and compliance policies
About the company
Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
1992
Get referred to Alexion
See people who can refer or advise you
Simplify's Take
What believers are saying
- AstraZeneca's July 2026 half-year revenue rose 9%, driven partly by Alexion's rare-disease growth.
- Ultomiris gained FDA Priority Review on June 15, 2026 for IgAN, with Q4 2026 decision.
- Koselugo's November 2025 adult NF1 approval and ALXN2220 phase 3 expand the pipeline.
What critics are saying
- EmblemHealth's April 2025 Soliris antitrust suit targets patent settlements and biosimilar delays.
- Soliris faces biosimilar erosion after March 2025, while Ultomiris still depends on C5-franchise switching.
- Ultomiris carries meningococcal boxed warnings; a single fatal infection can trigger litigation and prescribing pullback.
What makes Alexion unique
- Alexion pioneered complement biology, turning C5 inhibition into approved medicines since Soliris, 2007.
- Ultomiris, Soliris, Strensiq, and Koselugo span hematology, nephrology, endocrinology, and oncology-adjacent rare diseases.
- AstraZeneca's 2021 acquisition gives Alexion global commercialization scale and deeper trial funding.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Stock Options
Company Equity
401(k) Retirement Plan
Mental Health Support
Wellness Program
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Professional Development Budget
Conference Attendance Budget
Training Programs
Tuition Reimbursement
Professional Certification Support
Mentorship Program
Parental Leave
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Childcare Support
Elder Care Support
Relocation Assistance
Employee Referral Bonus
Meal Benefits
Commuter Benefits
Legal Services
Employee Discounts
Company Social Events
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
2%"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."
Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM. Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM
WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”
WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2
Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease. . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old